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Abstract
BACKGROUND—Prostate cancer linkage studies have been used to localize rare and presumably
highly penetrant cancer susceptibility genes. Underlying genetic heterogeneity, as well as the high
sporadic background of the disease, has resulted in many signals that are often not reproducible
between research studies.
METHODS—We conducted a SNP-based genome wide linkage scan on 131 Caucasian prostate
cancer families participating in the University of Michigan Prostate Cancer Genetics Project (PCGP).
RESULTS—The strongest evidence for linkage was detected at 16q23 (LOD = 2.70 at rs1079635).
Prostate cancer linkage to the same region of 16q23 has been observed by others and the region
contains several strong candidate genes including the known prostate cancer tumor suppressor genes
ATBF1 and WWOX. This linkage signal was not detected in our prior linkage study on 175 PCGP
families, illustrating the genetic heterogeneity underlying prostate cancer susceptibility.
CONCLUSIONS—Further linkage studies in combination with tumor analyses from linked families
are in progress to identify the putative hereditary prostate cancer gene at 16q23.
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Prostate cancer is the most common cancer diagnosed among American men and the second
leading cause of cancer deaths with an estimated 186,320 new cases and 28,660 deaths expected
in the United States in 2008 [1]. The significance of a heritable component in prostate cancer
is undeniable as evidenced by findings from segregation analyses, genome-wide linkage and
association scans, as well as twin and other family-based epidemiologic studies [2]. However,
the localization of highly penetrant prostate cancer susceptibility genes has proven to be
extremely difficult. Prostate cancer is a clinically heterogeneous disease with complex genetic
underpinnings. The majority of the genetic variants that are consistently associated with an
increased risk of prostate cancer to this point are not highly penetrant and are relatively common
(>5%) across populations [3]. Genome-wide prostate cancer association studies are specifically
powered to detect common, low-penetrant variants associated with the disease, but are not
designed to detect rare, highly penetrant disease causing mutations. Whole genome-wide
linkage studies of families with multiple affected relatives have been successful for identifying
genes containing mutations that are associated with enhanced susceptibility to cancers of the
breast, ovary, colorectum, endometrium and skin (melanoma), but not prostate, likely due in
part to the large number of pre-clinical cancers detected as a result of PSA screening. Despite
the challenges, a large collaborative linkage study on 1,233 prostate cancer families conducted
by the International Consortium on Prostate Cancer Genetics (ICPCG) [4] has identified several
chromosomal regions of interest based on suggestive evidence of linkage (LOD scores >1.86)
including 5q12, 8p21, 15q11, 17q21, and 22q12. The aim of the current investigation is to
provide further clues in the search for prostate cancer susceptibility genes by conducting a
genome-wide linkage scan on new families recruited into an established study of early-onset
and/or hereditary prostate cancer.
MATERIALS AND METHODS
Since its inception in 1995, the goal of the Prostate Cancer Genetics Project (PCGP) has been
to identify genes predisposing to inherited forms of prostate cancer. Enrollment into the PCGP
is restricted to (1) men diagnosed with prostate cancer with at least one living first-or second-
degree relative also diagnosed with prostate cancer or (2)men diagnosed with prostate cancer
at ≤55 years of age without a family history of the disease. Eligibility criteria for inclusion in
PCGP linkage studies are more stringent and include (1) at least three related family members
with prostate cancer (or two cases with an average age at diagnosis ≤56 years) and (2) DNA
available on at least two cases that are informative for linkage analysis. Prostate cancer
diagnoses are confirmed by medical record whenever possible. Otherwise, independent
confirmation of the diagnosis by at least two family members is required. All subjects provide
written informed consent to participate in the study and for release of pertinent medical records.
The protocol and consent documents were approved by the University of Michigan Medical
School Institutional Review Board. DNA samples were collected and genotyped from 471
individuals from 131 families, including 352 diagnosed cases. The current investigation is
limited to Caucasian families due to the small number of African American families (n = 6)
collected and the marked differences in allele frequencies and linkage disequilibrium patterns
between African American and Caucasians.
Clinical data abstracted from medical records was used to classify prostate cancer into either
aggressive or non-aggressive forms. The definition of clinically aggressive disease in this study
was identical to the definition used in our previous genome-wide scan of aggressive disease
[5], and similar to the definitions used by other investigative teams participating in the ICPCG
[6]. Specifically, affected men were considered to have aggressive disease if they met at least
one of the following criteria: (1) regional or distant stage based on pathology if radical
prostatectomy was done, otherwise clinical stage [American Joint Commission on Cancer
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(AJCC) stage III (T3, N0, M0) or stage IV (T4, N0, M0) or any T, N1, M0 or any T, N0, M1];
(2) Gleason grade at diagnosis of≥7 (or poorly differentiated grade if no Gleason score was
available); (3) pre-diagnostic PSA≥20 ng/ml; or (4) prostate cancer listed as the primary cause
of death on a death certificate. Men without any of these criteria were coded as unknown for
the linkage analyse of aggressive disease.
Genomic DNA was prepared from blood samples using standard techniques. DNA samples
were sent to the Center for Inherited Disease Research (CIDR) for genotyping. CIDR performs
SNP genome scan linkage genotyping using Illumina’s Human Linkage-12 Marker Panel. This
panel includes 5,871 SNP loci spread across the genome at an average marker density of 0.43
cM coverage among Caucasians.
Statistical Methods
Genome-wide multipoint nonparametric linkage analyses were performed over a 1 cM grid
using the computer software package Merlin [7]. The “Pairs” score statistic [8] was used to
identify chromosomal regions with excess identity-by-descent allele sharing among affected
relatives. Equal weights were assumed for all pedigrees; the exponential model [9] was used
to convert nonparametric linkage (NPL) Z-scores to LOD scores. Allele frequencies were
estimated using all available data from all 131 Caucasian PCGP families included in this study
and inter-marker distances and order were provided by CIDR. Merlin’s “–rsq 0.1” command
was used to cluster together markers in linkage disequilibrium to avoid the upward bias in LOD
scores caused by including markers with non-independent genotypes in the pedigree founders.
Linkage analyses were performed separately for all 131 Caucasian PCGP families and for a
subset of 57 informative families that had two or more related cases of aggressive prostate
cancer. For the aggressive disease linkage analyses, men with non-aggressive prostate cancer
had their phenotype recoded as “unknown.” Pedigrees were included in this analysis if there
were at least two genetically related men with aggressive disease and if they were informative
for linkage.
RESULTS
Of the 131 PCGP families included in the current genome scan, the average age of diagnosis
among prostate cancer cases was 61.9 years with 72% of families having an average age of
diagnosis among confirmed cases of ≤65 years. Fifty-four percent of cases were characterized
as having aggressive disease and 57 (43.5%) families had two or more cases classified as
aggressive. The average number of affected men per family was 3.8 and 59 families (44%) had
four or more relatives with prostate cancer. A comparison of the characteristics of families in
the current analysis with the 175 PCGP families included in our first genome scan is presented
in Table I.
Although no significant evidence of linkage was detected in the genome-wide linkage analysis,
two regions (chromosomes 1p [LOD=1.89] and 16q [LOD = 2.70]) were detected to have
suggestive evidence for linkage based on Lander and Kruglyak’s [10] definition (LOD>1.86)
(Fig. 1). Modest positive LOD scores were observed at the five chromosomal regions with
suggestive linkage identified by the ICPCG [1,4]: 5q12 (LOD = 0.18), 8p21 (LOD = 0.52),
15q11 (LOD = 0.35), 17q21 (LOD = 0.28), and 22q12 (LOD = 0.28). Weak evidence for linkage
was also found in regions identified by genetic association studies, namely 8q24 (LOD = 0.59)
and 17q12 (LOD = 0.23), but no evidence was found at 17q24 (LOD = 0.00). The maximum
LOD score observed for each chromosome is presented in Table II.
From the 131 PCGP families, 57 families had multiple cases of aggressive prostate cancer and
were informative for nonparametric linkage analysis. Two regions had suggestive evidence for
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linkage to aggressive prostate cancer (chromosomes 9q [LOD = 2.96] and 10q [LOD = 1.96])
(Fig. 1 and Table II).No evidence for linkage (LOD = 0.00) was detected at 6p22, the region
with the strongest suggestive linkage in the study of aggressive prostate cancer by the ICPCG
[6].
DISCUSSION
In this genome wide scan of the 131 families recruited most recently into the Prostate Cancer
Genetics Project, the evidence for prostate cancer linkage was strongest at 16q23 (LOD = 2.70;
near rs1079635). Furthermore, in a subset of 57 pedigrees with two or more cases of aggressive
prostate cancer, strongly suggestive evidence for aggressive prostate cancer linkage was
observed at 9q33 (LOD = 2.96; near rs1405). LOD scores of greater than one were also
observed on chromosomes 1, 2, 3, 4, 7, 8, 10, 14, and 15 either on all pedigrees and/or the
subset of families with aggressive prostate cancer.
Our linkage signal on chromosome 16q is illustrated in more detail in Figure 2. The marker
nearest the peak is rs1079635 which is in an intron of the WWOX (WW domain-containing
oxidoreductase) gene which maps to 16q23.3-q24.1. The 1-LOD support interval is
approximately 7.4 megabases; it contains 30 known genes in addition to WWOX as well as a
number of unknown transcripts.
Prior linkage studies have demonstrated evidence for prostate cancer linkage at 16q23 [11–
13]. In a genome-wide scan of 504 brothers with prostate cancer from 230 families, Suarez et
al. [11] reported evidence for linkage on a ~16.8cM region on 16q23 (multipoint Z-scor = 3.15
for marker D16S3096). Note that D16S3096 is approximately 1 Mb telomeric to rs1079635.
Evidence for linkage (P = 0.009) was also found at 16q23 in a second independent genome-
wide screen on 259 brothers from the same group [13]. A genome-wide scan on 12 hereditary
prostate cancer families, each having one family member diagnosed with pancreatic cancer,
also displayed some evidence for linkage at 16q23 (Kong and Cox LOD = 1.05 at D16S3098;
P = 0.01) [14]. D16S3098 is approximately 4 Mb from rs1079635 and is within the 2-LOD,
but not the 1-LOD support interval of our linkage signal.
Tumor studies have demonstrated multiple regions with loss of heterozygosity on chromosome
16q that included 16q23 [15]. Paris et al. [16] reported significant LOH at D16S3096 and
D16S516 (45% and 53%, respectively) in 51 prostate tumor samples. Although the tumors in
this study were not specifically limited to men with hereditary prostate cancer, the allelic
imbalance observed at markers D16S3096 and D16S516 was associated with family history of
prostate cancer, suggesting the existence of a tumor suppressor gene in this region.
As previously noted, there are several candidate genes under our linkage peak, but the most
obvious gene for further consideration is the tumor-suppressor gene WWOX [17]. The
WWOX gene is large (>1 Mb), encodes a protein containing over 400 amino acids and overlaps
with the second most common human fragile site, FRA16D [18]. LOH and reduced expression
of the WWOX protein are common in a number of human cancers including prostate cancer
[17]. The fact that the WWOX gene is frequently inactivated in human cancers has fueled the
theory that it acts as a tumor suppressor gene. In pursuing this hypothesis, several studies have
shown that overexpression of WWOX inhibits growth in a variety of cell lines [18]. Aqeilan et
al. [19] in a study of mice with a targeted deletion of WWOX, observed that 30% of homozygous
knockouts developed spontaneous osteosarcomas and all homozygotes died before 4 weeks of
age, preventing further analysis of adult tumor incidence. Seventeen percent (10/58) of
heterozygotes developed a variety of tumors including lymphomas, liver, gastric and lung over
the next 18 months of follow-up as compared to less than 2% (1/60) of the wild type mice,
further supporting the notion that WWOX plays a critical role in tumorigenesis.
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Although WWOX is centered within our linkage peak, additional candidate genes are within
the 1-LOD support interval (Figure 2). The transcription factor ATBF1 was shown by Sun et
al. [20] to contain somatic mutations in 36% of cancers and some of these mutations appear to
impair function. The breast cancer antiestrogen resistance 1 (BCAR1) gene expression has been
shown to be inversely correlated with 16q23 LOH [21]. A panel of six genes that map to 16q23-
ter were shown to be consistently downregulated in prostate cancer compared to normal
prostate tissue including two genes in our 1-LOD support interval: WWOX and the transcription
factor MAF [22].
A limited number of studies have been conducted to identify aggressive prostate cancer genes,
and no such study has reported significant or suggestive evidence of linkage for aggressive
prostate cancer to 9q33. Analysis of 188 hereditary prostate cancer families from Johns
Hopkins University showed evidence for prostate cancer linkage to 9q34 (LOD = 2.17; near
marker D9S1825), but this report did not focus on aggressive prostate cancer [23]. A number
of studies have performed quantitative trait linkage analyses on Gleason score, a measure of
prostate cancer aggressiveness. Witte et al. [13] reported modest evidence for linkage to 9q34
(LOD = 1.2, P = 0.009 near marker D9S1825) when analyzing Gleason score. Candidate genes
on chromosome 9q include the T-cell acute lymphoblastic leukemia 2 (TAL2) gene which is
altered in approximately 25% of T-cell leukemias and the deleted in bladder cancer 1
(DBC1) gene.
Previously, the PCGP conducted a whole genome linkage scan on 175 independent prostate
cancer families and a subsequent analysis of aggressive prostate cancer on a subset of 71
pedigrees with two or more cases of aggressive prostate cancer [5,24]. The families
participating in the first genome scan do not overlap with the families genotyped for the current
analysis. The initial genome-wide scan on the first 175 PCGP families revealed suggestive
linkage to 17q21 (LOD = 2.36). The subsequent analysis in a subset of 71 pedigrees with 2 or
more cases of aggressive prostate cancer provided significant evidence for linkage at 15q12
(LOD = 3.49) and suggestive evidence at 6p22 (LOD = 2.09) [5]. In the current study, only
modest evidence for prostate cancer linkage was observed at 17q21 (LOD = 0.28) and no
evidence for aggressive prostate cancer linkage was detected at 6p22 or 15q12 (LOD = 0.00
at both locations). Conversely, no evidence for prostate cancer linkage was detected in the first
175 PCGP pedigrees at 16q23 (LOD = 0.00) or for aggressive prostate cancer linkage at 9q33
(LOD = 0.07).
The inconsistent linkage results between the first 175 pedigrees and the current 131 PCGP
pedigrees inevitably calls into question the similarity between families included in the original
genome-wide scan and the new families. To address this issue, a comparison of the clinical
characteristics reveal that the prostate cancer cases among families in the current scan are on
average approximately 2 years younger at the time of diagnosis compared to the cases from
the original families (Table I). Otherwise, the two sets of pedigrees were remarkably similar
with respect to the number of cases with aggressive disease and the number of confirmed
affected relatives per family.
The inconsistency of linkage results across different studies continues to plague genome-wide
linkage scans of prostate cancer and has been largely attributed to not only the genetic, but also
the clinical heterogeneity of the disease. One potential solution is stratified analysis, creating
homogenous clinical strata according to disease aggressiveness, the influence of family history
and age of diagnosis. This strategy requires large pools of affected individuals accomplished
through combining participants from multiple studies, and further requires consistent clinical
definition across studies and employing methods to correct findings to reduce the probability
of spurious positive results due to multiple comparisons [2]. This has been one of the principal
goals in the formation of the ICPCG. In this study of 131 PCGP pedigrees, we found weak
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supportive evidence for linkage to all five identified regions in the collaborative report by the
ICPCG, namely: 5q12 (LOD = 0.18), 8p21 (LOD = 0.52), 15q11 (LOD = 0.35), 17q21 (LOD
= 0.28), and 22q12 (LOD = 0.28). Clearly, given the tremendous genetic and phenotypic
heterogeneity of prostate cancer, a substantial number of additional prostate cancer families
will have to be collected, analyzed and combined before any final conclusions can be drawn
regarding the validity of linkage at each of these regions.
CONCLUSIONS
In summary, prostate cancer linkage studies have been used for localizing regions of the
genome to target for candidate gene searches. The previous studies implicating 16q23 have all
included sibships and families from the same research team [11–13]. For the first time, we
have independently confirmed prostate cancer linkage to 16q23 using a set of families collected
by the University of Michigan PCGP. This region has been intently studied based on the
observation that deletion of 16q markers is commonly seen in sporadic cancers of many types
including prostate cancer. Our linkage report should stimulate renewed research interest in this
genomic region, and we believe that use of families with linkage evidence in combination with
tumor studies should facilitate the discovery of any 16q23 tumor suppressor gene that
contributes to prostate cancer susceptibility.
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Genome-wide linkage results for prostate cancer from 131 PCGP families (gray dashed line)
and aggressive prostate cancer from 57 PCGP families with two or more cases of aggressive
prostate cancer (solid black line).
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Linkage results for all 131 families at 16q.The1-LOD support interval (redlines) is defined by
markers rs71953 andrs1125733.Candidate genes ATBF1, BCAR1,WWOX, and MAF, as well
as the microsatellite marker D16S3096, are each within the 1-LOD support interval. The 2-
LOD support interval is defined by markers rs716455 and rs7190151, and microsatellite marker
D16S3098 is within the 2-LOD but not the 1-LOD support interval. The six genes that were
reported by Watson et al. [22] to show reduced expression in prostate cancer compared to
normal prostate tissue using quantitative expression analysis are:WWOX,WFDC1, MAF,
FOXF1, MVD and predicted transcript Q9H0B8.
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TABLE I




(Caucasian families) Second GWS
No. of families 175 157 131
Mean age at diagnosis (SD) among affected
relatives
64 years (5.7 years) 64 years (5.6 years) 62 years (6.3 years)
% of families with average age of diagnosis
≤65 years
61% 61% 72%
Mean number of confirmed affected relatives
(SD)
3.9 (1.8) 3.8 (1.5) 3.8 (1.4)
% of families with four or more affected
relatives
45% 43% 44%





Aggressive disease defined as having T stage 3 and higher or N1 or M1 or Gleason grade of ≥7, or pre-diagnostic PSA of >20 ng/ml or prostate cancer
listed as primary cause of death on the death certificate.
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